Thus, in order to evaluate PTM as a potential anticancer drug, the expression levels of the S100B and p53 proteins were quantified in human biopsies that were derived from controls, peritumoral tissues, ulcerative colitis, and colon cancer patients, at baseline and after the addition of PTM-loaded niosomes. This evidence concerns the gene TP53 and malignant colon neoplasm.